Belimumab

I Sanz, U Yasothan, P Kirkpatrick - Nature Reviews Drug Discovery, 2011 - go.gale.com
I Sanz, U Yasothan, P Kirkpatrick
Nature Reviews Drug Discovery, 2011go.gale.com
In March 2011, belimumab (Benlysta; Human Genome Sciences/GlaxoSmithKline), a human
monoclonal antibody that is specific for the cytokine B lymphocyte stimulator, was approved
by the US Food and Drug Administration (FDA) for the treatment of systemic lupus
erythematosus.Systemic lupus erythematosus (SLE) is a complex autoimmune disease that
can affect multiple organ systems, including the kidneys, the skin, the lungs, the heart and
the central nervous system (CNS)(1). It is characterized by a recurring and variable pattern …
In March 2011, belimumab (Benlysta; Human Genome Sciences/GlaxoSmithKline), a human monoclonal antibody that is specific for the cytokine B lymphocyte stimulator, was approved by the US Food and Drug Administration (FDA) for the treatment of systemic lupus erythematosus.
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect multiple organ systems, including the kidneys, the skin, the lungs, the heart and the central nervous system (CNS)(1). It is characterized by a recurring and variable pattern of disease flare and remission, and its presentation can range from mild symptoms to potentially lift-threatening kidney or cardiovascular involvement (1). Although the use of traditional immunosuppressive agents such as corticosteroids and cyclophosphamide have improved the treatment of SLE in the past decade, a substantial proportion of patients do not achieve full remission and the majority experience relapses despite long-term immunosuppressive therapy, which can be associated with an increased risk of infection and cancer (1).
Gale